Search

Displaying results 6071 - 6080 of 10000 in total
  1. Drug

    Meticrane

    go.drugbank.com/drugs/DB13284
    Approved

    It has been marketed in Japan under the trade name Arresten and is used to lower blood pressure [L5647].

  2. Drug

    Palazestrant

    go.drugbank.com/drugs/DB18971
    Investigational

    Palazestrant is under investigation in clinical trial NCT06016738 (OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).

  3. Drug

    D-3082-L

    go.drugbank.com/drugs/DB17440
    Experimental

    D-3082-L is one of the components of the human papilloma virus (HPV) type 16 E6/E7 synthetic long peptide (SLP) vaccine ISA101b.

    Synonyms: Human Papilloma Virus (HPV) Type 16 E6/e7 Synthetic Long Peptide (SLP) Vaccine Component D-3082-L
  4. Drug

    Reproterol

    go.drugbank.com/drugs/DB12846
    Investigational

    Reproterol has been used in trials studying the treatment of Asthma, Exercise-Induced.

  5. Drug

    BI-K0376

    go.drugbank.com/drugs/DB05858
    Experimental

    BI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.

  6. Drug

    OM85

    go.drugbank.com/drugs/DB16533
    Investigational

    OM-85, a bacterial extract, is an immunomodulator of interferon-β production and inflammasome activity.

  7. Drug

    E-2012

    go.drugbank.com/drugs/DB05171
    Experimental

    E-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.

  8. Drug

    Methylmethionine chloride

    go.drugbank.com/drugs/DB13250
    Experimental

    Methylmethionine chloride may be useful in helping the healing of gastric ulcers. In Japan, it is used as an over the counter product for gastrointestinal health support.

  9. Drug

    GW906

    go.drugbank.com/drugs/DB34002
    Experimental

    GW906 is under investigation in clinical trial NCT07835984 (A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two

  10. Drug

    Valdecoxib

    go.drugbank.com/drugs/DB00580
    ApprovedWithdrawn

    Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.